PL2993186T3 - Przeciwciało monoklonalne i sposób jego otrzymywania - Google Patents

Przeciwciało monoklonalne i sposób jego otrzymywania

Info

Publication number
PL2993186T3
PL2993186T3 PL15171431T PL15171431T PL2993186T3 PL 2993186 T3 PL2993186 T3 PL 2993186T3 PL 15171431 T PL15171431 T PL 15171431T PL 15171431 T PL15171431 T PL 15171431T PL 2993186 T3 PL2993186 T3 PL 2993186T3
Authority
PL
Poland
Prior art keywords
monoclonal antibody
monoclonal
antibody
Prior art date
Application number
PL15171431T
Other languages
English (en)
Inventor
Ramakrishnan Melarkode
Pradip Nair
Sundaraj David Rajkumar
Kedarnath Nanjund Sastry
Monalisa Chatterji
Laxmi Adhikary
Hema Balasubramanian
Jose Enrique Montero Casimiro
Josefa Lombardero Valladares
Rolando Perez Rodriguez
Original Assignee
Biocon Limited
Centro De Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41064805&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2993186(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocon Limited, Centro De Inmunologia Molecular filed Critical Biocon Limited
Publication of PL2993186T3 publication Critical patent/PL2993186T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL15171431T 2008-03-14 2008-09-04 Przeciwciało monoklonalne i sposób jego otrzymywania PL2993186T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN650CH2008 2008-03-14
EP08873217A EP2265644A4 (en) 2008-03-14 2008-09-04 MONOCLONAL ANTIBODY AND CORRESPONDING METHOD
PCT/IN2008/000562 WO2009113083A1 (en) 2008-03-14 2008-09-04 A monoclonal antibody and a method thereof
EP15171431.8A EP2993186B1 (en) 2008-03-14 2008-09-04 A monoclonal antibody and a method thereof

Publications (1)

Publication Number Publication Date
PL2993186T3 true PL2993186T3 (pl) 2020-02-28

Family

ID=41064805

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15171431T PL2993186T3 (pl) 2008-03-14 2008-09-04 Przeciwciało monoklonalne i sposób jego otrzymywania

Country Status (26)

Country Link
US (6) US8524233B2 (pl)
EP (2) EP2993186B1 (pl)
JP (3) JP2011513479A (pl)
KR (1) KR20100126811A (pl)
CN (1) CN101970493A (pl)
AR (1) AR072247A1 (pl)
AU (1) AU2008352540B2 (pl)
BR (1) BRPI0822447A2 (pl)
CA (1) CA2716919C (pl)
CL (1) CL2009000618A1 (pl)
CO (1) CO6331445A2 (pl)
DK (1) DK2993186T3 (pl)
EA (1) EA201001467A1 (pl)
ES (1) ES2759075T3 (pl)
HK (1) HK1223941A1 (pl)
IL (1) IL207917A0 (pl)
MX (1) MX2010010085A (pl)
MY (1) MY159517A (pl)
NZ (1) NZ587632A (pl)
PL (1) PL2993186T3 (pl)
PT (1) PT2993186T (pl)
TW (1) TWI485160B (pl)
UA (1) UA104587C2 (pl)
UY (1) UY31710A (pl)
WO (1) WO2009113083A1 (pl)
ZA (1) ZA201005843B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY154819A (en) * 2006-12-26 2015-07-31 Centro Inmunologia Molecular Pharmaceutical compositions with capacity to induce adoptosis in tumor cells for the diagnosis and treatment of the b-cell chroniclymphocytic leukemia
BRPI0822447A2 (pt) 2008-03-14 2015-06-16 Biocon Ltd Anticorpo monoclonal e método do mesmo
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3590949T3 (da) 2010-10-01 2022-07-11 Modernatx Inc Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151667A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
KR102062784B1 (ko) * 2013-07-23 2020-01-07 바이오콘 리미티드 단백질 내 푸코실화 수준을 제어하는 방법
NZ746944A (en) 2013-07-23 2021-07-30 Biocon Ltd Use of a cd6 binding partner and method based thereon
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
CN104497141B (zh) * 2014-12-31 2017-10-10 百泰生物药业有限公司 抗人cd6分子的治疗性抗体
JP6930916B2 (ja) * 2015-02-12 2021-09-01 ユニヴァーシティ オブ サザン カリフォルニアＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｓｏｕｔｈｅｒｎ Ｃａｌｉｆｏｒｎｉａ 疾患予防および治療における成長ホルモン受容体の遮断剤
WO2017218750A1 (en) 2016-06-15 2017-12-21 The Cleveland Clinic Foundation Novel anti-cd6 antibodies for treating t-cell mediated conditions
AU2017345390A1 (en) * 2016-10-18 2019-05-02 Biocon Limited Use of itolizumab to reduce phosphorylation of CD6
DK3529274T3 (da) * 2016-10-21 2024-06-17 Biocon Ltd Monoklonalt antistof og fremgangsmåde til anvendelse til behandling af lupus
CN108178797B (zh) * 2017-12-29 2020-12-01 西南大学 一种抗家蚕BmSRC多克隆抗血清、制备方法及应用
EP3759140A1 (en) 2018-02-27 2021-01-06 Equillium, Inc. Anti cd6 antibodies for treating severe asthma
WO2020006568A1 (en) * 2018-06-29 2020-01-02 City Of Hope Cd6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders
BR112021016967A2 (pt) 2019-02-26 2021-11-23 Equillium Inc Composições de anticorpo anti-cd6 e métodos para tratar lúpus
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
AU2021287998A1 (en) 2020-06-11 2023-02-02 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
WO2023036349A1 (es) 2021-09-08 2023-03-16 Centro De Inmunologia Molecular Uso de anticuerpos monoclonales anti-cd6 en la prevención del daño celular y orgánico derivado de una respuesta hiper-inflamatoria

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US699755A (en) 1902-03-06 1902-05-13 Ira G Hoag Train-order box in connection with semaphores.
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0631783A1 (en) 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
AU703694B2 (en) 1993-11-02 1999-04-01 Bristol-Myers Squibb Company CD6 ligand
US5998172A (en) 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP1516628B1 (en) 1995-07-27 2013-08-21 Genentech, Inc. Stable isotonic lyophilized protein formulation
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
EA002271B1 (ru) 1996-03-20 2002-02-28 Хехст Марион Руссель ТРИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ В ОТНОШЕНИИ ИНТЕГРИНОВ, В ЧАСТНОСТИ В ОТНОШЕНИИ ИНТЕГРИНА АЛЬФАvБЕТА 3, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, ИСПОЛЬЗУЕМЫЕ В ЭТОМ СПОСОБЕ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МЕДИКАМЕНТОВ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
EP0977991A4 (en) * 1997-03-03 2004-12-15 Bristol Myers Squibb Co MONOCLONAL ANTIBODIES FOR HUMAN CD6
WO1998047531A2 (en) * 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
WO2000058362A1 (en) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
CA2372603C (en) 1999-05-07 2015-11-17 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
JP2003527861A (ja) * 2000-03-16 2003-09-24 ジェネンテック・インコーポレーテッド 増強した抗血液凝固能を持つ抗組織因子抗体
EP1283721A4 (en) * 2000-05-26 2004-07-07 Smithkline Beecham Corp ANTI-RANK-LIGAND-BINDING MONOCLONAL ANTIBODIES USEFUL FOR TREATING DISEASES CAUSED BY THE RANK-LIGANDS
ES2192128B1 (es) 2001-04-27 2005-01-01 Universidad De Vigo Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
WO2004019861A2 (en) 2002-08-28 2004-03-11 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
PL1610820T5 (pl) 2003-04-04 2014-01-31 Genentech Inc Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
ES2337473T3 (es) 2004-02-19 2010-04-26 Genentech, Inc. Anticuerpos reparadores con cdr.
AU2005250499B2 (en) 2004-06-03 2011-12-08 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
JP4652414B2 (ja) 2004-11-12 2011-03-16 ゼンコー・インコーポレイテッド ＦｃＲｎとの変化した結合を有するＦｃ変異体
EP1841456A2 (en) 2005-01-28 2007-10-10 Wyeth Stabilized liquid polypeptide formulations
WO2007142667A2 (en) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
KR20090021298A (ko) 2006-06-14 2009-03-02 임클론 시스템즈 인코포레이티드 항-ｅｇｆｒ 항체의 동결건조 제제
MX2009006199A (es) 2006-12-11 2009-06-22 Hoffmann La Roche Formulacion parenteral de anticuerpos abeta.
CN101199483B (zh) 2006-12-14 2011-01-26 上海中信国健药业股份有限公司 一种稳定的抗her2人源化抗体制剂
UY30838A1 (es) * 2006-12-26 2008-07-31 Centro Inmunologia Molecular Composicion farmacéutica que comprende un anticuerpo monoclonal anti cd6 utilizado en el diagnostico y tratamiento de la artritis reumatoide
MY154819A (en) 2006-12-26 2015-07-31 Centro Inmunologia Molecular Pharmaceutical compositions with capacity to induce adoptosis in tumor cells for the diagnosis and treatment of the b-cell chroniclymphocytic leukemia
AU2008204901A1 (en) 2007-01-09 2008-07-17 Wyeth Anti-IL-13 antibody formulations and uses thereof
KR20100014568A (ko) 2007-02-28 2010-02-10 쉐링 코포레이션 가공된 항-ｉｌ-23ｒ 항체
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2009002521A2 (en) 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
WO2009037190A2 (en) 2007-09-21 2009-03-26 F. Hoffmann-La Roche Ag Pharmaceutical formulation for il-ir antibody
BRPI0822447A2 (pt) 2008-03-14 2015-06-16 Biocon Ltd Anticorpo monoclonal e método do mesmo
EP2356146A1 (en) 2008-11-07 2011-08-17 Fabrus Llc Anti-dll4 antibodies and uses thereof
PT3721904T (pt) 2009-11-20 2021-11-15 Biocon Ltd Formulações de anticorpo t1h
CN102559636B (zh) 2011-12-30 2014-03-12 百泰生物药业有限公司 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
KR102062784B1 (ko) 2013-07-23 2020-01-07 바이오콘 리미티드 단백질 내 푸코실화 수준을 제어하는 방법
NZ746944A (en) 2013-07-23 2021-07-30 Biocon Ltd Use of a cd6 binding partner and method based thereon
WO2017218750A1 (en) 2016-06-15 2017-12-21 The Cleveland Clinic Foundation Novel anti-cd6 antibodies for treating t-cell mediated conditions
AU2017345390A1 (en) 2016-10-18 2019-05-02 Biocon Limited Use of itolizumab to reduce phosphorylation of CD6
DK3529274T3 (da) 2016-10-21 2024-06-17 Biocon Ltd Monoklonalt antistof og fremgangsmåde til anvendelse til behandling af lupus
US11198851B2 (en) 2016-10-28 2021-12-14 Inserm (Institut National De La Sante Et De La Rechere Medicale) Ex vivo generation of γδ Foxp3+ regulatory T cells and therapeutic uses thereof
EP3759140A1 (en) 2018-02-27 2021-01-06 Equillium, Inc. Anti cd6 antibodies for treating severe asthma
BR112021016967A2 (pt) 2019-02-26 2021-11-23 Equillium Inc Composições de anticorpo anti-cd6 e métodos para tratar lúpus
US20230151107A1 (en) 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
CA3201076A1 (en) 2020-12-04 2022-06-09 Stephen Connelly Methods of selectively targeting cd6 high cells and decreasing activity of t eff cells

Also Published As

Publication number Publication date
ZA201005843B (en) 2011-04-28
ES2759075T3 (es) 2020-05-07
EP2993186A1 (en) 2016-03-09
US10669346B2 (en) 2020-06-02
AU2008352540B2 (en) 2012-06-28
UA104587C2 (ru) 2014-02-25
EP2265644A4 (en) 2011-04-27
MY159517A (en) 2017-01-13
TWI485160B (zh) 2015-05-21
EA201001467A1 (ru) 2011-06-30
US20210122829A1 (en) 2021-04-29
JP2011513479A (ja) 2011-04-28
CL2009000618A1 (es) 2011-05-27
KR20100126811A (ko) 2010-12-02
JP2014065711A (ja) 2014-04-17
NZ587632A (en) 2012-06-29
PT2993186T (pt) 2019-11-29
MX2010010085A (es) 2011-03-29
US20160168256A1 (en) 2016-06-16
CO6331445A2 (es) 2011-10-20
US8524233B2 (en) 2013-09-03
CA2716919A1 (en) 2009-09-17
US11981743B2 (en) 2024-05-14
US20180258179A1 (en) 2018-09-13
HK1223941A1 (zh) 2017-08-11
WO2009113083A1 (en) 2009-09-17
EP2265644A1 (en) 2010-12-29
US9217037B2 (en) 2015-12-22
TW201000125A (en) 2010-01-01
US10000573B2 (en) 2018-06-19
US20170281808A1 (en) 2017-10-05
US20110002939A1 (en) 2011-01-06
AU2008352540A1 (en) 2009-09-17
DK2993186T3 (da) 2019-11-25
UY31710A (es) 2009-11-10
CA2716919C (en) 2015-01-20
BRPI0822447A2 (pt) 2015-06-16
US20140031529A1 (en) 2014-01-30
JP2014159425A (ja) 2014-09-04
AR072247A1 (es) 2010-08-18
IL207917A0 (en) 2010-12-30
EP2993186B1 (en) 2019-09-04
US9670285B2 (en) 2017-06-06
CN101970493A (zh) 2011-02-09
JP5856209B2 (ja) 2016-02-09

Similar Documents

Publication Publication Date Title
HK1223941A1 (zh) 單克隆抗體及其方法
SG10201601279SA (en) Monoclonal Antibody STRO-4
EP2331579A4 (en) MONOCLONAL ANTIBODIES
IL201082A0 (en) Bispecific antibodies and methods for production thereof
EP2021373A4 (en) MONOCLONAL ANTIBODY VCAM-1 SPECIFIC
HK1194395A1 (zh) 抗體及其製備和使用方法
PT2374883T (pt) Anticorpo anti-cd4
ZA200809662B (en) Modified humanised anti-interleukin-18 antibodies
ZA201005348B (en) Humanized anti-c5ar antibodies
ZA201207484B (en) Humanized anti-egfl7 antibodies and methods using same
PL2510011T3 (pl) Przeciwciała monoklonalne, które wiążą B7H6 i ich zastosowania
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
EP2006379A4 (en) HIGHLY FUNCTIONAL BISPECIFIC ANTIBODY
IL204835A0 (en) Humanized antibody
EP2322562A4 (en) MONOCLONAL ANTIBODY AND IMMUNASSAY WITH IT
EP2114996A4 (en) ALLERGEN BINDING IGE MONOCLONAL ANTIBODIES AND METHOD FOR PREPARING HYPOALLERGENES
SI2094728T1 (sl) Postopki za uporabo za humano-adaptivnost monoklonskih protiteles
EP2495319A4 (en) MONOCLONAL ANTIBODY SPECIFIC TO INTEGRIN alpha8beta1
HK1158977A1 (zh) 抗膜鐵轉運蛋白 單克隆抗體及其用途
EP2313777A4 (en) METHOD OF IDENTIFYING ANTIBODIES
GB0804687D0 (en) Humanized antibody
GB0804684D0 (en) Humanized antibody
GB0804686D0 (en) Humanized antibody
GB0706963D0 (en) Humanized antibody
GB0706965D0 (en) Humanized antibody